Rare Cancers Australia (RCA) is determined to increase awareness, highlight the need for further research and initiate policy discussion and action to improve the lives and outcomes of all Australians living with a rare or less common cancer. RCA is currently working with government, clinicians and industry for change.
2018/2019 Annual Review
A report on the major progress made by Rare Cancers Australia - Innovation Against Inequality.
Rare Solutions: A Time to Act
First report of its kind paves the way for government, industry and research community to unite to improve access and outcomes for Australian patients.
Submission to Senate Inquiry for the Availability and Accessibility of Diagnostic Imaging Equipment around Australia
This submission addresses the availability and accessibility which is a diagnostic imaging equipment - such as ultrasound, computed tomography (CT), nuclear medicine, radiography (x-ray), magnetic resonance imaging (MRI) and positron emission tomography (PET) - in Australia.
Diagnostic imaging is a critical part of the cancer journey and our submission can be downloaded below.
View our response to the Committee's recommendations here.
Submission to Senate Inquiry for Funding Research into Cancers with Low Survival Rates
This submission addresses the urgent need for improved funding into research for cancers with low survival rates, many of which are rare or less common.
A transcript of our CEO Richard Vines' address to the senate inquiry public hearing can be found here
RCA Cancer Patient Organisations in Asia Report
The need for patient groups to provide constructive input into the shape and priorities of health services within the Asia region.
Just a Little More Time: Rare Cancers Update Report
2016 update on the status of rare and less common cancers in Australia, including patient outcomes, research and treatment funding.
Just a Little More Time
Details incidence, mortality and survival rates and also examines current funding levels for research and treatment.
Access to Cancer Medicines Senate Inquiry
This submission was presented to the Senate Community Affairs Committee and addresses the shortfalls of our current medicines funding and access model. It offers two recommendations to improve the system.
Funding for Treatment of Rare Cancers in Australia
A survey of pharmaceutical company employees, physicians and patient/advocacy group members.
PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options for subsidy consideration for multiple cancer types
PD-1 and PD-L1 checkpoint inhibitor immunotherapies: options for subsidy consideration for multiple cancer types (pan-tumour)